Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3026
Vanda Pharmaceuticals
VNDA
$304M
| $1.68M | ﹤0.01% |
191,036
-31,543
| -14% | -$174K |
|
3027
Symbotic
SYM
$5.43B
| $1.68M | ﹤0.01% |
28,311
+28,280
| +91,226% | +$1.87M |
|
|
AHRT
3028
AH Realty Trust
AHRT
$506M
| $1.68M | ﹤0.01% |
254,277
+40,625
| +19% | +$268K |
|
3029
Perella Weinberg Partners
PWP
$1.33B
| $1.68M | ﹤0.01% |
96,903
+2,183
| +2% | +$40.7K |
|
3030
Crawford & Co Class A
CRD.A
$632M
| $1.67M | ﹤0.01% |
148,795
+6,543
| +5% | +$72.2K |
|
|
AMWD
3031
DELISTED
American Woodmark
AMWD
| $1.67M | ﹤0.01% |
31,045
+5,547
| +22% | +$325K |
|
3032
Kforce
KFRC
$1.08B
| $1.66M | ﹤0.01% |
53,813
+6,362
| +13% | +$187K |
|
|
PSTL
3033
Postal Realty Trust
PSTL
$701M
| $1.66M | ﹤0.01% |
102,994
+57,354
| +126% | +$882K |
|
|
MBX
3034
MBX Biosciences
MBX
$3.23B
| $1.66M | ﹤0.01% |
52,691
+31,065
| +144% | +$754K |
|
3035
CALL
Otis Worldwide
OTIS
$27.8B
| $1.66M | ﹤0.01% |
19,000
+18,800
| +9,400% | +$1.68M |
|
3036
CALL
IBM
IBM
$223B
| $1.66M | ﹤0.01% |
5,600
-1,400
| -20% | -$419K |
|
|
PDM
3037
Piedmont Realty Trust
PDM
$1.2B
| $1.66M | ﹤0.01% |
198,784
+18,868
| +10% | +$158K |
|
3038
SandRidge Energy
SD
$516M
| $1.65M | ﹤0.01% |
114,618
+8,689
| +8% | +$115K |
|
3039
Aveanna Healthcare
AVAH
$2.46B
| $1.65M | ﹤0.01% |
202,356
+22,997
| +13% | +$208K |
|
3040
Ooma
OOMA
$574M
| $1.65M | ﹤0.01% |
140,647
+14,324
| +11% | +$163K |
|
3041
CALL
Trip.com Group
TCOM
$28.3B
| $1.65M | ﹤0.01% |
22,900
| – | – |
|
3042
Fox Factory Holding Corp
FOXF
$886M
| $1.64M | ﹤0.01% |
95,975
+10,193
| +12% | +$194K |
|
|
ESPR
3043
DELISTED
Esperion Therapeutics
ESPR
| $1.64M | ﹤0.01% |
443,339
+107,730
| +32% | +$348K |
|
3044
Patria Investments
PAX
$1.88B
| $1.64M | ﹤0.01% |
103,142
+10,415
| +11% | +$156K |
|
|
MAZE
3045
Maze Therapeutics
MAZE
$1.54B
| $1.64M | ﹤0.01% |
39,508
+11,992
| +44% | +$412K |
|
|
SPYM
3046
CALL
State Street SPDR Portfolio S&P 500 ETF
SPYM
$170B
| $1.64M | ﹤0.01% |
+20,400
| New | +$1.62M |
|
|
SPYM
3047
PUT
State Street SPDR Portfolio S&P 500 ETF
SPYM
$170B
| $1.64M | ﹤0.01% |
+20,400
| New | +$1.62M |
|
3048
CALL
Kohl's
KSS
$2.22B
| $1.63M | ﹤0.01% |
80,000
-707,500
| -90% | -$13.3M |
|
|
FIGR
3049
Figure Technology Solutions
FIGR
$7.05B
| $1.63M | ﹤0.01% |
39,976
+22,776
| +132% | +$911K |
|
3050
Yext
YEXT
$613M
| $1.63M | ﹤0.01% |
201,955
+21,390
| +12% | +$180K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.